RemeGen Co., Ltd. (HKG:9995)

Market Cap	55.93B +2.5%
Revenue (ttm)	9.24B +286.2%
Net Income	6.72B
EPS	11.99
Shares Out	559.97M
PE Ratio	5.56
Forward PE	12.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,736,767
Open	67.80
Previous Close	68.35
Day's Range	65.90 - 68.10
52-Week Range	63.30 - 123.10
Beta	0.46
Analysts	Buy
Price Target	117.32 (+76.02%)
Earnings Date	Oct 30, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,145
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 16 analysts, the average rating for 9995 stock is "Buy." The 12-month stock price target is $117.32, which is an increase of 76.02% from the latest price.

Price Target

$117.32

(76.02% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 14, 2026

Data Sources Report a data error